相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells
Maria L. Lotsberg et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms
Mark Borris D. Aldonza et al.
SCIENCE ADVANCES (2020)
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
Donghwa Kim et al.
CELL DEATH & DISEASE (2019)
Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation
Markus Lauter et al.
CELL COMMUNICATION AND SIGNALING (2019)
General Mechanisms Leading to Persister Formation and Awakening
Dorien Wilmaerts et al.
TRENDS IN GENETICS (2019)
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Chenjing Zhu et al.
MOLECULAR CANCER (2019)
EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer
Eugene Tulchinsky et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells
Kei Namba et al.
MOLECULAR CANCER RESEARCH (2019)
Antibiotic collateral sensitivity is contingent on the repeatability of evolution
Daniel Nichol et al.
NATURE COMMUNICATIONS (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
Marie-Anne Goyette et al.
CELL REPORTS (2018)
Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells
Duc-Hiep Bach et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Quantitative phase imaging in biomedicine
YongKeun Park et al.
NATURE PHOTONICS (2018)
BMP4 Upregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells
Duc-Hiep Bach et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Regulated intramembrane proteolysis of the AXL receptor kinase generates an intracellular domain that localizes in the nucleus of cancer cells
Yinzhong Lu et al.
FASEB JOURNAL (2017)
Apoptotic Bodies Elicit Gas6-Mediated Migration of AXL-Expressing Tumor Cells
Annelien J. M. Zweemer et al.
MOLECULAR CANCER RESEARCH (2017)
Rare cell variability and drug- induced reprogramming as a mode of cancer drug resistance
Sydney M. Shaffer et al.
NATURE (2017)
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Matthew J. Hangauer et al.
NATURE (2017)
Combating subclonal evolution of resistant cancer phenotypes
Samuel W. Brady et al.
NATURE COMMUNICATIONS (2017)
Paraoxonase-1 (PON1) induces metastatic potential and apoptosis escape via its antioxidative function in lung cancer cells
Mark Borris D. Aldonza et al.
ONCOTARGET (2017)
A tool for discovering drug sensitivity and gene expression associations in cancer cells
Yong Qin et al.
PLOS ONE (2017)
Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer
Andrew Dhawan et al.
SCIENTIFIC REPORTS (2017)
Giving AXL the axe: targeting AXL in human malignancy
Carl M. Gay et al.
BRITISH JOURNAL OF CANCER (2017)
Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
Boyang Zhao et al.
CELL (2016)
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio et al.
CELL (2016)
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Michael Ramirez et al.
NATURE COMMUNICATIONS (2016)
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
Hidenori Kitai et al.
CANCER DISCOVERY (2016)
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Miles A. Miller et al.
CANCER DISCOVERY (2016)
Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions
Song Yi Bae et al.
SCIENTIFIC REPORTS (2016)
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Hyo-eun C. Bhang et al.
NATURE MEDICINE (2015)
Collateral sensitivity of antibiotic-resistant microbes
Csaba Pal et al.
TRENDS IN MICROBIOLOGY (2015)
Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
Song Yi Bae et al.
ONCOTARGET (2015)
Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells
Mark Borris Docdoc Aldonza et al.
PLOS ONE (2015)
AXL Mediates Resistance to Cetuximab Therapy
Toni M. Brand et al.
CANCER RESEARCH (2014)
Addressing Genetic Tumor Heterogeneity through Computationally Predictive Combination Therapy
Boyang Zhao et al.
CANCER DISCOVERY (2014)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
Aaron S. Meyer et al.
SCIENCE SIGNALING (2013)
Quantitative Phase Imaging Techniques for the Study of Cell Pathophysiology: From Principles to Applications
KyeoReh Lee et al.
SENSORS (2013)
Biology of the TAM Receptors
Greg Lemke
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Targeting the ERBB family in cancer: couples therapy
Niall Tebbutt et al.
NATURE REVIEWS CANCER (2013)
Collateral sensitivity as a strategy against cancer multidrug resistance
Kristen M. Pluchino et al.
DRUG RESISTANCE UPDATES (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
Robert J. Gillies et al.
NATURE REVIEWS CANCER (2012)
Growth Inhibition of Human Lung Cancer Cells via Down-regulation of Epidermal Growth Factor Receptor Signaling by Yuanhuadine, a Daphnane Diterpene from Daphne genkwa
Ji-Young Hong et al.
JOURNAL OF NATURAL PRODUCTS (2011)
Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib
Vince D. Cataldo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Daphnane Diterpene Esters with Anti-proliferative Activities against Human Lung Cancer Cells from Daphne genkwa
Ji-Young Hong et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2010)
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
Chad J. Creighton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Beyond chemotherapy: targeted therapies in ovarian cancer
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2009)
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
Stuart Thomson et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma
Barbara A. Frederick et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Novel diterpenoids with potent inhibitory activity against endothelium cell HMEC and cytotoxic activities from a well-known TCM plant Daphne genkwa
ZJ Zhan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2005)
分享论文
